Big Pharma
1 April 2025 MSD, Novartis and Eli Lilly are among those whose multi-billion-dollar patents are hurtling towards expiration, writes Marisa Woutersen.
13 March 2025
27 February 2025
Latest Features
Americas
Smaller US companies can now choose to take on much larger, foreign opponents at the ITC, explain Cristen Corry, Paul Ainsworth and Uma Everett of Sterne Kessler.
Americas
Will this year be defined by a concerted shift towards ‘One Health’? Simon Kiddle and Rebecca Tollervey of Mewburn Ellis explore.
Americas
Key developments for the industry this year include a more pro-patent administration and USPTO changes, say Carla Ji-Eun Kim and Deborah Sterling of Sterne Kessler.
Americas
The act’s one-sided provisions and its disproportionate remedies cannot pass constitutional muster, argues John Cox of Barnes & Thornburg.
Asia
Recent updates to China’s patent law provide guidelines on PTA calculations, definitions of delays and challenging decisions, say Audrey Cheung, Yolanda Wang and Jennifer Che of Eagle IP.
Americas
Can the FTC push through a law that has perturbed America’s life sciences industry? Unlikely, says the lawyer appointed by the world’s largest HR group opposing the move.
Europe
As the company challenges Pfizer and BioNTech over COVID-19 vaccine patents, issues over the enforceability of pledges made during the pandemic may make pharma think twice in future, finds Marisa Woutersen.
Big Pharma
Kerri-Ann Limbeek, trial lead for Ravgen, tells Sarah Speight that a compelling narrative was key to winning the case against their larger rival.
More News
20 February 2025 Market leader settles patent disputes with generic drug makers, blocking the release of versions of two key products | More than 80% of HIV patients in the US use Gilead’s treatments.
6 February 2025 Oral hearings heard the USPTO side with MSD (Merck) over a term extension for a reissued patent, in a case set to have huge implications for pharma market exclusivity, reports Marisa Woutersen.
30 January 2025 UK court confirms it cannot depart from CJEU law | SPC application for multiple sclerosis treatment rejected | Judges stress that any change to the SPC framework needs legislative reform not interpretation.
30 January 2025 Five-strong team to open new location in the spring | Office will be led by experienced litigators and patent specialists bringing pharma, biologics, medical devices, femtech, and technology expertise to Chicago.
29 January 2025 Complex legal battle concerns ‘skinny label’ strategy used by generic drug makers, prompting a $235 million award | Pharma giant looks for enhanced damages due to ‘wilful infringement’, while opponent wants another trial.
28 January 2025 Munich division asks pharma company for clarity on territorial scope | Sanofi took battle with four generic makers over Jevtana to UPC.
23 January 2025 Teva insisted panel’s narrow interpretation of ‘claims the drug’ will have a seismic effect on the Orange Book | Stay granted while en banc rehearing is under question | Decision could reshape patent listing standards and impact the availability of generic drugs.
Get up-to-date information on all our publications and events
Get critical life sciences news direct to your inbox